NASDAQ:KALAKala Pharmaceuticals Stock Price, Forecast & News

Kala Pharmaceuticals' stock was trading at $7.63 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, KALA stock has increased by 61.3% and is now trading at $12.31. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kala Pharmaceuticals.

Kala Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Kala Pharmaceuticals.

Kala Pharmaceuticals Inc (NASDAQ:KALA) issued its quarterly earnings results on Thursday, May, 7th. The company reported ($0.54) EPS for the quarter, missing the Zacks' consensus estimate of ($0.51) by $0.03. The company had revenue of $1.07 million for the quarter, compared to the consensus estimate of $2.49 million. Kala Pharmaceuticals had a negative net margin of 1,578.64% and a negative return on equity of 132.08%. View Kala Pharmaceuticals' earnings history.

5 brokerages have issued 1 year price objectives for Kala Pharmaceuticals' shares. Their forecasts range from $15.00 to $35.00. On average, they expect Kala Pharmaceuticals' share price to reach $20.40 in the next twelve months. This suggests a possible upside of 65.7% from the stock's current price. View analysts' price targets for Kala Pharmaceuticals.

Media headlines about KALA stock have trended extremely negative on Sunday, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kala Pharmaceuticals earned a news sentiment score of -5.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutKala Pharmaceuticals.

Some companies that are related to Kala Pharmaceuticals include Amarin (AMRN), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Turning Point Therapeutics (TPTX), Insmed (INSM), Karuna Therapeutics (KRTX), Intercept Pharmaceuticals (ICPT), Ra Pharmaceuticals (RARX), Prestige Consumer Healthcare (PBH), Principia Biopharma (PRNB), TG Therapeutics (TGTX), IGM Biosciences (IGMS), Eidos Therapeutics (EIDX) and Passage Bio (ZNTL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Bristol-Myers Squibb (BMY), Amarin (AMRN), Alibaba Group (BABA), Clovis Oncology (CLVS), Micron Technology (MU), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Verastem (VSTM) and Inovio Pharmaceuticals (INO).

(KALA) raised $90 million in an initial public offering on Thursday, July 20th 2017. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

Kala Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (19.93%), Orbimed Advisors LLC (9.90%), Eventide Asset Management LLC (5.41%), BlackRock Inc. (4.10%), Vivo Capital LLC (1.44%) and Driehaus Capital Management LLC (0.92%). Company insiders that own Kala Pharmaceuticals stock include Gregory Grunberg, Howard B Rosen, Ra Capital Healthcare Fund Lp, Rajeev M Shah and Todd Bazemore. View institutional ownership trends for Kala Pharmaceuticals.

KALA stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Alyeska Investment Group L.P., Wedbush Securities Inc., Wells Fargo & Company MN, Morgan Stanley, UBS Group AG, Greenwich Wealth Management LLC, and Legal & General Group Plc. View insider buying and selling activity for Kala Pharmaceuticals.

KALA stock was acquired by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Eventide Asset Management LLC, Orbimed Advisors LLC, Vivo Capital LLC, Driehaus Capital Management LLC, Invesco Ltd., Ensign Peak Advisors Inc, and EAM Investors LLC. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Gregory Grunberg, Howard B Rosen, Ra Capital Healthcare Fund Lp, Rajeev M Shah, and Todd Bazemore. View insider buying and selling activity for Kala Pharmaceuticals.

Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KALA stock can currently be purchased for approximately $12.31.

Kala Pharmaceuticals has a market capitalization of $671.76 million and generates $6.07 million in revenue each year. The company earns $-94,350,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis. Kala Pharmaceuticals employs 136 workers across the globe.

The official website for Kala Pharmaceuticals is www.kalarx.com.

Kala Pharmaceuticals' mailing address is 100 BEAVER STREET SUITE 201, WALTHAM MA, 02472. The company can be reached via phone at 781-996-5252 or via email at [email protected]